

Ref. No: 1488  
Date: 23/01/25  
Subject: Diffuse Large B Cell Lymphoma (DLBCL)

**REQUEST**

**Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?**

**Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?**

**Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:**

**R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**

**R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**

**Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**

**Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)**

**R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)**

**R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)**

**R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)**

**(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)**

**R-GemOX (rituximab, gemcitabine and oxaliplatin)**

**Axicabtagene ciloleucel**

**Tisagenlecleucel**

**Epcoritamab**

**Loncastuximab tesirine**

**Glofitamab**

**Any other SACT**

**Stem cell transplant or bone marrow transplant (autologous or allogeneic)**

**Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):**

**Axicabtagene ciloleucel (Yescarta)**

**Tisagenlecleucel**

**Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**

**R-GemOX (rituximab, gemcitabine and oxaliplatin)**

**Stem cell transplant or bone marrow transplant (autologous or allogeneic)**

**Any other treatments**

**Q4. In the last 6 months, how many patients has the Trust has treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?**

**Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:**

**CAR-T Therapy (E.g. Axicabtagene ciloleucel)**

**Stem cell transplant or bone marrow transplant (autologous or allogeneic)**

**Any other treatment**

**RESPONSE**

**Q1.**

**Patients diagnosed 01.06.24 – 30.11.24 with primary Diffuse Large B Cell Lymphoma (DLBCL)**

MWL
20

**Q1a.**

**Started treatment at diagnosing Trust:**

MWL
18

**Q2.**

**In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:**

Pola-R-CHP – 12 patients

RCHOP – 13 patients

**Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):**

Pola-BR – <5 patient

RGCVP – <5 patient

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.

**Q4. In the last 6 months, how many patients has the Trust has treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?**

0

**Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:**

This information is not held.